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Abstract
The mutant products Q279E (279Gln to Glu) and R301Q (301Arg to Gln) of the X-chromosomal inherited K-galactosidase
(EC 3.2.1.22) gene, found in unrelated male patients with variant Fabry disease (late-onset cardiac form) were characterized.
In contrast to patients with classic Fabry disease, who have no detectable K-galactosidase activity, atypical variants have
residual enzyme activity. First, the properties of insect cell-derived recombinant enzymes were studied. The Km and Vmax
values of Q279E, R301Q, and wild-type K-galactosidase toward an artificial substrate, 4-methylumbelliferyl-K-D-
galactopyranoside, were almost the same. In order to mimic intralysosomal conditions, the degradation of the natural
substrate, globotriaosylceramide, by the K-galactosidases was analyzed in a detergent-free-liposomal system, in the presence
of sphingolipid activator protein B (SAP-B, saposin B). Kinetic analysis revealed that there was no difference in the
degradative activity between the mutants and wild-type K-galactosidase activity toward the natural substrate. Then,
immunotitration studies were carried out to determine the amounts of the mutant gene products naturally occurring in cells.
Cultured lymphoblasts, L-57 (Q279E) and L-148 (R301Q), from patients with variant Fabry disease, and L-20 (wild-type)
from a normal subject were used. The 50% precipitation doses were 7% (L-57) and 10% (L-148) of that for normal
lymphoblast L-20, respectively. The residual K-galactosidase activity was 3 and 5% of the normal level in L-57 and L-148,
respectively. The quantities of immuno cross-reacting materials roughly correlated with the residual K-galactosidase activities
in lymphoblast cells from the patients. Compared to normal control cells, fibroblast cells from a patient with variant Fabry
disease, Q279E mutation, secreted only small amounts of K-galactosidase activity even in the presence of 10 mM NH4Cl. It is
concluded that Q279E and R301Q substitutions do not significantly affect the enzymatic activity, but the mutant protein
levels are decreased presumably in the ER of the cells. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The degradation of glycolipids is accomplished in
lysosomes through the sequential actions of endogly-
cosidases. An inherited de¢ciency of the lysosomal
enzyme leads to the accumulation of its substrates
in lysosomes [1]. The genetic defect of K-galactosi-
dase (EC 3.2.1.22) encoded by a gene localized to
the X-chromosomal region, Xq22, results in Fabry
disease. This disease is characterized by the systemic
intralysosomal accumulation of neutral sphingolipids
with terminal K-galactosyl moieties, predominantly
globotriaosylceramide (GbOse3Cer), in cells of the
heart, kidneys, and vascular endothelial system [2].
Atypical Fabry variants with residual enzyme ac-
tivity and cardiomyopathy of late-onset have been
reported [3^5], and a screening study revealed that
these variants comprised 3% of unrelated male pa-
tients with left ventricular hypertrophy referred to a
cardiology clinic in Japan [6]. In cases with this car-
diac form, four single base substitutions were de-
tected in the upstream region of exon 6 of the K-
galactosidase gene, 279Gln to Glu (Q279E) [3],
301Arg to Gln (R301Q) [4], and 296Met to Val
(M296V) [5] or Ile (M296I) [6]. Recently, an unre-
lated Japanese male patient carrying the R301Q mu-
tation who only presented nephropathy, rather than
cardiomyopathy, was reported [7].
Since, the lymphoblast cells derived from patients
with variant Fabry disease, Q279E and R301Q, tran-
scribed K-galactosidase mRNAs of normal size and
normal amounts [3,4], we wanted to clarify in this
paper whether those mutations a¡ect the enzyme’s
activity toward the natural substrate or result in an
abnormal posttranslational decrease of the enzyme
level. First, we focused our attention on the degra-
dation of GbOse3Cer by a recombinant K-galactosi-
dase mutant with the Q279E or R301Q substitution,
using a detergent-free-liposomal system, in the pres-
ence of sphingolipid activator protein B (SAP-B),
since, in vivo hydrolysis of GbOse3Cer is stimulated
by SAP-B [8]. Then, using immunotitration proce-
dures, the amounts of the two mutants and wild-
type K-galactosidase naturally occurring in the pro-
bands lymphoblast cells were determined. Intracellu-
lar processing of mutant K-galactosidase, Q279E,
was analyzed in patient’s ¢broblasts in the presence
of either NH4Cl or leupeptin.
2. Materials and methods
2.1. Materials
Restriction enzymes were purchased from Nippon
Gene (Tokyo, Japan). Spodoptera frugiperda clonal
isolate 9 (Sf9) cells, vector plasmid pAcYM1 [9],
and wild-type Autographa californica nuclear poly-
hedrosis virus (AcNPV) were supplied by Dr. A. Ta-
kase (National Institute of Neuroscience, Tokyo, Ja-
pan). Egg phosphatidylcholine and D,L-K-tocopherol
were from Sigma (Deisenhofen, Germany). Protein
A^Sepharose, concanavalin A (Con A)^Sepharose,
and Mono Q HR 5/5 were from Amersham Pharma-
cia Biotech (Uppsala, Sweden). 4-Methylumbellifer-
yl-K-D-galactopyranoside was from Nacalai Tesque
(Kyoto, Japan). Lichroprep RP-18 was from Merck
(Darmstadt, Germany). Leupeptin was from Peptide
Institute (Osaka, Japan). Other reagents were of the
highest grade available.
2.2. Cell culture
The Epstein^Barr virus-transformed lymphoblast
lines from a normal adult (L-20) and two atypical
Fabry patients (L-57 and L-148) were cultured in
RPMI-1640 medium (Nissui, Tokyo, Japan) supple-
mented with 10% fetal calf serum (FCS) at 37‡C
under 5% CO2.
Skin ¢broblast cell lines derived from a normal
adult (F-591) and an atypical Fabry patient (F-
374), Q279E mutation, were maintained in Ham’s
F-10 medium (Gibco BRL, Grand Island, NY,
USA) supplemented with 10% FCS, and were grown
to con£uency at 37‡C under 5% CO2. Leupeptin was
included in the culture medium (3 ml in a 60-mm
dish) at a ¢nal concentration of 1 mM for 4 days
[10]. The normal culture medium above con£uent
cultures in 10-cm dishes was replaced by FCS-free
medium (10 ml) supplemented with NH4Cl at a ¢nal
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concentration of 10 mM. Four days later, the me-
dium was collected and 30-fold concentrated by ul-
tra¢ltration with Centriprep 10 (Amicon, Denvers,
MA, USA) and enzyme activity was measured in
30-Wl aliquot [11].
Sf9 cells were were cultured in Grace’s medium
(Gibco BRL) supplemented with 10% FCS at 25‡C.
2.3. Expression and puri¢cation of recombinant
human K-galactosidase
The cDNA for human K-galactosidase (1.3 kb)
was subcloned into the BamHI site of pAcYM1,
the resultant vector being designated as pAcGal
[12]. The expression vectors for the K-galactosidase
mutants (Q279E and R301Q) were constructed by
directional cloning of fragments containing the mu-
tation site into pAcGal. Clone pBa57 for the Q279E
mutant [3] or pBa148 for the R301Q mutant [3] was
digested with BglII and KpnI. The resultant two
kinds of 0.5-kb fragments were puri¢ed by electro-
phoresis, and then inserted into pAcGal in place of
the corresponding fragment (pAcQ279E or
pAcR301Q), respectively. After co-transfection of
AcNPV DNA and an expression vector (pAcGal,
pAcQ279E, or pAcR301Q) into Sf9 cells, the re-
combinant viruses were selected by the limiting-dilu-
tion method and propagated. Sf9 cells were infected
with a recombinant virus and then cultured in serum-
free Grace’s medium for 4 days. The expressed K-
galactosidase mutants were puri¢ed from the culture
medium by Con A^Sepharose and Mono Q column
chromatographies [13]. Electrophoresis (12% poly-
acrylamide gel) was carried out by the method of
Laemmli under reducing conditions [14].
2.4. K-Galactosidase activity toward an arti¢cial
substrate and protein concentration determination
K-Galactosidase activity was measured with an ar-
ti¢cial substrate as described by Kusiak et al. [15]
with the following modi¢cation. The reaction mix-
ture (50 Wl), comprising 5 mM 4MU-K-D-galactopyr-
anoside in 0.1 M sodium citrate bu¡er, pH 4.6, was
incubated at 37‡C for 6 min. The reaction was termi-
nated with 0.7 ml of 0.1 M glycine bu¡er, pH 10.6.
The K-galactosidase activity of cell homogenate or
culture medium was assayed under the conditions
described above, except for 1^2 h incubation with
120 mM N-acetylgalactosamine (Sigma, St. Louis,
MO, USA) as an inhibitor of K-N-acetylgalactosami-
nidase [16].
The protein amounts of cell homogenates were
determined by means of the Bio-Rad dye-binding
assay (Bio-Rad, Hercules, CA, USA), using bovine
serum albumin as the standard. The protein concen-
trations of the recombinant mutants (Q279E and
R301Q) and wild-type K-galactosidase were deter-
mined as to absorbance at 280 nm with an extinction
coe⁄cient of 18.1 [17].
2.5. Thermostability of the recombinant
K-galactosidases
Wild-type and the mutant (Q279E and R301Q) K-
galactosidases, 1.7^2.0 Wg, were incubated at 50‡C in
25 mM MES bu¡er, pH 6.0, the ¢nal volume was
100 Wl. At various time intervals, samples were re-
moved and assayed for residual activity toward
4MU-K-D-galactopyranoside.
2.6. K-Galactosidase activity toward
globotriaosylceramide in a detergent-free
liposomal system
K-Galactosidase activity toward GbOse3Cer was
measured according to the method described previ-
ously [13]. In brief, liposomes with a total lipid con-
centration of 2 Wmol/ml were prepared from egg
phosphatidylcholine, 93% (mol/mol), D,L-K-tocopher-
ol, 2% (mol/mol), and GbOse3Cer, tritiated at the
terminal galactose to a speci¢c activity of 7.7 Ci/
mol, 5% (mol/mol). To obtain large unilamellar lipo-
somes (80.0 þ 25 nm), the lipid preparation was ex-
truded 19 times through an extrusion device (Liposo
Fast-Basic; Avestin, Ottawa, Canada) using 100-nm-
pore polycarbonate membranes.
The K-galactosidase assay mixture comprised lipo-
somes (10 Wl, 1 nmol of tritiated GbOse3Cer), a mu-
tant or the wild-type K-galactosidase (enzyme activ-
ity, 2.4 nmol of arti¢cial substrate hydrolyzed per
min), 2 Wg of puri¢ed human SAP-B [18], 50 mM
sodium citrate bu¡er, pH 4.6, and bovine serum al-
bumin (5 Wg), in a total volume of 50 Wl. After in-
cubation at 37‡C, the reaction was terminated by the
addition of 50 Wl of methanol and then the reaction
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mixture was loaded onto a small reverse-phase col-
umn of RP-18 (0.25 ml). After washing of the col-
umn with 100 Wl of a chloroform/methanol/0.1 M
aqueous KCl solution, 3:48:47 (v/v/v), the liberated
tritiated galactose was eluted with 2 ml of water, and
the radioactivity was measured with a scintillation
counter. Control radioactivity was measured by add-
ing SAP-B and the enzyme only after termination of
the incubation.
2.7. Immunotitration
Lymphoblast cells were collected by centrifuga-
tion, suspended in 25 mM MES bu¡er, pH 6.0,
and then sonicated. Then the cell homogenate (40
Wg of protein) was centrifuged at 10 000Ug at 4‡C
for 10 min. The cell supernatant was incubated with
3^500 ng of an IgG preparation (prepared from rab-
bit antiserum raised against the puri¢ed recombinant
human K-galactosidase derived from insect-cells, us-
ing protein A^Sepharose) [19] in 25 mM MES bu¡er,
pH 6.0, containing bovine serum albumin (1 mg/ml),
the ¢nal volume being adjusted to 40 Wl. After 4 h
incubation at 4‡C, 30 Wl of a protein A^Sepharose
suspension (1:1) in the last bu¡er was added. After
30 min gentle rotation, all tubes were centrifuged at
3000Ug for 5 min. The supernatants were assayed
for K-galactosidase activity toward 4MU-K-D-galac-
topyranoside.
3. Results
3.1. Puri¢cation and characterization of the
K-galactosidase mutants (Q279E or R301Q)
expressed in insect cells
The recombinant K-galactosidase mutants (Q279E
and R301Q) found in the variant form of the Fabry
disease were puri¢ed and characterized. The ¢nal
preparation of each, the two mutants and the wild-
type K-galactosidase, gave a slightly broad and single
band in SDS^polyacrylamide gel electrophoresis cor-
responding to 46-kDa (Fig. 1). To assess their ther-
mostability, the recombinant K-galactosidases were
incubated at 50‡C in a bovine serum albumin-free
MES bu¡er, pH 6.0. As shown in Fig. 2, they were
almost completely inactivated after 30 min, while the
wild-type K-galactosidase retained 43% of its original
activity even after 60 min.
Fig. 1. Sodium dodecyl sulfate/polyacrylamide gel (12%) electro-
phoresis of the puri¢ed recombinant mutant and wild-type K-
galactosidase under reducing conditions. Four Wg of each en-
zyme protein was applied and stained with Coomassie brilliant
blue R-250. Wild-Type, wild-type K-galactosidase; Q279E,
Q279E mutant K-galactosidase; R301Q, R301Q mutant K-galac-
tosidase.
Fig. 2. Stability of recombinant mutants (Q279E or R301Q)
and wild-type K-galactosidase at 50‡C, pH 6.0. K-Galactosidase
activity was monitored with 4-methylumbelliferyl-K-D-galacto-
pyranoside. The initial enzyme activities (100%) were 4.2, 3.8,
and 5.0 nmol/min/100 Wl for Q279E (b), R301Q (a), and wild-
type K-galactosidase (F), respectively.
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3.2. Degradation of arti¢cial and natural substrates
by the wild-type and mutant K-galactosidases
The kinetic properties of two mutants and wild-
type K-galactosidase are summarized in Table 1.
The pH optimum of the two mutants was 4.6, cor-
responding to that of the wild-type K-galactosidase.
The Km value toward 4MU-K-D-galactopyranoside
was slightly lower for the wild-type K-galactosidase
than for the two mutants. The Vmax value of the
Q279E mutant was similar to that of the wild-type
K-galactosidase, and the Vmax of R301Q was slightly
lower than those of Q279E and the wild-type. These
results indicated that both the mutations, i.e. Q279E
and R301Q, had no signi¢cant e¡ects on the enzy-
matic properties of the K-galactosidase molecule to-
ward the arti¢cial substrate.
Using a detergent-free liposomal system, the deg-
radation of the natural substrate, GbOse3Cer, by the
two mutant enzymes was analyzed in the presence of
SAP-B, in order to mimic intralysosomal conditions
(Fig. 3). There was a linear relationship between en-
zyme activity and reaction time until 2 h. Time
course analysis revealed that there were no signi¢cant
di¡erences in the degradation activity toward the
natural substrate between the two mutants and the
wild-type K-galactosidase. In particular, the Q279E
mutant and wild-type enzymes exhibited almost the
same degradation ability. This indicates that both the
two mutations do not a¡ect the enzymatic activity
toward the natural substrate.
3.3. Amounts of K-galactosidase mutant enzymes in
cultured lymphoblasts from patients with variant
Fabry disease
To characterize the naturally occurring K-galacto-
sidase mutant gene products, residual enzyme activ-
ities and residual protein levels were studied in cul-
tured lymphoblasts, L-57 (Q279E) and L-148
(R301Q) obtained from patients with variant Fabry
disease, and in wild-type lymphoblasts (L-20) ob-
tained from a normal subject. The residual K-galac-
tosidase activity in L-57 was 3% and that in L-148
was 5% of the normal level (L-20), respectively. Ad-
ditionally, the residual K-galactosidase activity exhib-
ited similar apparent Km values, 3.2 mM (L-57) and
3.0 mM (L-148) compared to 2.8 mM for the normal
enzyme (L-20), toward a £uorogenic substrate. To
clarify the relationship between the residual enzyme
activity and the protein amounts of the K-galactosi-
dase mutants in these lymphoblast cells, immunoti-
tration experiments were carried out, using antibod-
ies raised against the recombinant wild-type K-
galactosidase (Fig. 4). Fifty percent precipitation
was observed with 15 ng (IgG per 40 Wg protein
per assay) for L-57 and 20 ng (IgG per 40 Wg protein
per assay) for L-148, which were estimated to be
7 and 10% of the normal level, respectively. The rela-
tive amounts of immuno cross-reacting materials al-
most corresponded to the residual K-galactosidase
activities observed in the lymphoblast cells. These
data suggested that the reduced activities of the mu-
Fig. 3. The degradation of globotriaosylceramide by a recombi-
nant mutant (Q279E or R301Q) and wild-type K-galactosidase
in a detergent-free-liposomal system. Assays were carried out in
the presence of 2 Wg of sphingolipid activator protein B and
mutant or wild-type K-galactosidase, the activity of each corre-
sponded to 2.4 nmol of 4-methylumbelliferyl-K-D-galactopyrano-
side hydrolyzed per min. The release of radiolabeled galactose
was quanti¢ed as described in Section 2. Each value is the
mean of duplicate determinations. Q279E mutant K-galactosi-
dase (a), R301Q mutant K-galactosidase (E), and wild-type K-
galactosidase (b).
Table 1
Kinetic properties of the mutants, Q279E and R301Q, and
wild-type K-galactosidase derived from insect cells
Km (mM) Vmax (Wmol/min/mg)
Q279E 2.8 36
R301Q 2.8 27
Wild-type 2.2 34
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tant K-galactosidases (Q279E and R301Q) in lym-
phoblasts mainly resulted from decreased amounts
of the expressed enzyme proteins.
3.4. Ammonium chloride induced secretion of
K-galactosidase
Mutant ¢broblasts (Q279E) secreted K-galactosi-
dase activity into the culture medium (-NH4Cl)
only 20% of the normal (wild-type) control level (Ta-
ble 2). The addition of 10 mM NH4Cl to the culture
medium resulted in a 3^5-fold increase of extracellu-
lar K-galactosidase activity in both cultures. When
growing the patient’s cells in the presence of 1 mM
leupeptin, the intracellular levels of K-galactosidase
remained low (8% of wild-type control, Table 2).
4. Discussion
The human K-galactosidase gene located on the X-
chromosome is approximately 12 kb long and con-
sists of seven exons. Its cDNA encodes a precursor
peptide of 429 amino acid residues including a 31-
residue signal peptide [2]. The Q279E [3] and R301Q
[4] substitutions are the gene mutations found in two
unrelated patients with variant Fabry disease. The
two male patients carrying the Q279E and R301Q
mutations, respectively, showed mild clinical mani-
festations at the age of 50^60 years, mainly cardiac
symptoms. The residual K-galactosidase activity in
mixed leukocytes from these patients was decreased
to about 4% of the normal control level [20]. Since,
the lymphoblast cells derived from these patients
transcribed K-galactosidase mRNAs of normal size
and normal amounts [3,4], we searched for the cause
of the decrease of K-galactosidase activity at the pro-
tein level. The protein levels of the mutated K-galac-
tosidases were analyzed in the patients’ lymphoblasts
and ¢broblasts, and the properties of the mutant
enzymes were investigated after their expression in
Sf9 insect cells using a baculo-virus expression sys-
tem. The transfected Sf9 cells secreted relatively high
amounts of the mutant (Q279E and R301Q) and
wild-type K-galactosidase. It has been reported that
the recombinant wild-type K-galactosidase expressed
in insect cells has molecular properties, N-terminal
amino acid sequence [17], the extinction coe⁄cient
at 280 nm [17], and the molecular mass [13]. How-
ever, the recombinant mutant enzymes (Q279E and
Fig. 4. Immunotitration of a naturally occurring mutant
(Q279E or R301Q) or wild-type K-galactosidase in lymphoblast
cells derived from patients with variant Fabry disease or a nor-
mal subject. K-Galactosidase was immunoprecipitated from the
cell supernatants with increasing amounts of anti-K-galactosi-
dase IgG, and then the enzyme activity was measured in the
supernatants, with 4-methylumbelliferyl-K-D-galactopyranoside
as the substrate. Experiments were run in triplicate, the devia-
tions were less than 5%. Lymphoblast cell line L-57, Q279E K-
galactosidase gene mutation (b) ; L-148, R301Q K-galactosidase
gene mutation (a) ; L-20, wild-type K-galactosidase gene (F).
Table 2
E¡ect of ammonium chloride and leupeptin on the K-galactosidase activity of ¢broblasts from a patient with variant Fabry disease
and a normal subject
K-Galactosidase mutation K-Galactosidase activity
Medium (nmol/h/ml) Cells (nmol/h/mg protein)
3NH4Cl +NH4Cla 3Leupeptin +Leupeptinb
Q279E 0.2 0.9 2.5 3.9
Wild-type 1.0 2.7 54.7 49.2
K-Galactosidase activity was measured as described in Section 2.
a10 mM NH4Cl added to the serum-free medium.
b1 mM Leupeptin added to the medium supplemented with 10% fetal calf serum.
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R301Q) showed a marked decrease in thermostability
(Fig. 2) which may be caused by small changes in the
protein folding. Signi¢cant di¡erences were not ob-
served between mutants and wild-type enzymes, nei-
ther in the circular dichronism spectra, the wave-
length range of 200^250 nm (data not shown), nor
in the binding to Con A^Sepharose during the puri-
¢cation [21^23]. The latter observation indicates that
the recombinant enzymes contain terminal K-D-glu-
cosyl or K-D-mannosyl residues. The presence of
mannose oligosaccharide chains on recombinant
wild-type K-galactosidase expressed in Sf9 cells is
also suggested by their sensitivity to glycopeptidase
F [17] and endoglycosidase H [24].
To clarify the pathogenesis underlying the variant
form of Fabry disease, we studied the degradative
activity of the mutant enzymes toward the natural
substrate, GbOse3Cer. As the hydrolysis of
GbOse3Cer is mediated by sphingolipid activator
protein B (SAP-B) [8], we used a detergent-free-lip-
osomal system containing SAP-B. Surprisingly, both
mutant enzymes, Q279E and R301Q, showed similar
degradative activity toward GbOse3Cer in the pres-
ence of SAP-B as the wild-type K-galactosidase(Fig.
3). The two mutants also showed almost normal Km
or Vmax for the arti¢cial substrate, 4MU-K-D-galac-
topyranoside (Table 1). Therefore, the two mutant K-
galactosidase gene products, Q279E and R301Q,
cannot be regarded as Km or Vmax mutant enzyme
proteins.
Since the quite normal molecular speci¢c activities
of the mutant enzymes cannot explain the K-galacto-
sidase activity de¢ciencies of the patients, we ana-
lyzed the protein levels of the mutant K-galactosi-
dases in the patients’ cultured lymphoblasts. The
results of immunotitration studies indicate that the
steady-state levels of the mutant K-galactosidase pro-
teins decreased to 7 and 10% of the normal level in
L-57 (Q279E) and L148 (R301Q), respectively (Fig.
4), which may explain the low residual K-galactosi-
dase activities of 3 and 5% of normal control in L-57
and L-148, respectively. Thus, some unknown defect
of posttranslational processing might occur in these
cells, allowing only small amounts of the mutant K-
galactosidases with enzymatic activity might reach
the lysosomes.
Insect cells secrete high amounts of mutant and
wild-type proteins. However, the patient’s ¢bro-
blasts, Q279E mutation, secrete only small amounts
of the mutant K-galactosidase, even in the presence
of ammonium chloride, indicating that the mutations
a¡ect intracellular transport of the patient’s enzyme
upstream of the trans-Golgi network, most likely be-
tween ER and the cis-Golgi. This notion is also in
agreement with the leupeptin experiment which indi-
cates that the mutated K-galactosidase, Q279E, is not
degraded by cysteine-proteases in the lysosomes. Pro-
teolytic degradation of mutated protein at the level
of the ER has been observed for many proteins, e.g.
L-hexosaminidase A [25] or glucocerebrosidase [26].
The accumulation of aggregate was observed pre-
viously in COS-1 cells over expressing either Q279E
or R301Q [27]. The cells expressing Q279E were
treated with brefeldin A or monensin, which inhibit
the transport from ER to cis-Golgi and from the
medial to the trans-Golgi compartment, respectively.
The results suggest that the loss of enzyme activity
and accumulation of the aggregates might occur in
the ER. This situation has been documented with the
protein product of the cystic ¢brosis (CF)-associated
gene, which is called the CF transmembrane conduc-
tance regulator (CFTR) [28]. The most common mu-
tation in CFTR, vF508, a deletion of phenylalanine
508, fails to tra⁄c to the correct cellular location. It
was proposed that the mutant CFTR is recognized as
abnormal by cellular quality control mechanisms and
is incompletely processed in the ER where it is sub-
sequently degraded [29,30].
The threshold theory has been proposed in 1983/84
[31] and has initially been demonstrated to be valid
by Leinekugel et al. for GM2 gangliosidoses and
metachromatic leukodystrophy [32], and later on
for other storage diseases [1]. The threshold theory
correlates onset and severity of a storage disease with
the residual activity of the degrading system within
the lysosome. This work also indicates that ¢broblast
cells derived from an atypical Fabry patient, Q279E
mutation, also showed residual intracellular K-galac-
tosidase activity about 5% of the normal level when
cultured in the medium supplemented with 10% FCS
(Table 2). Many more samples are necessary to cal-
culate the critical threshold of Fabry disease, and
further analysis may constitute a theoretical model
of this disease.
However, there still remains the important point
that one patient, carrying the R301Q mutation, pre-
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sented only nephropathy [7], rather than cardiomy-
opathy, which is a major symptom in other variant
Fabry patients with point mutations in exon 6. The
reason for the di¡erence in organ susceptibility to the
same point mutation is not clear at present. Di¡erent
phenotypes of relatives carrying the same mutation
have been reported before, e.g. for the W226X mu-
tation [33] and the E341K mutation [34] in a Russian
family with Fabry disease. It is unclear, why in some
cases the onset of symptoms is delayed for decades
and in late-onset cases often a considerable pheno-
typic variation is observed even among siblings, who
must have the same mutation. The nature of the
molecular defect alone, however, cannot explain the
variability of the resulting clinical phenotype, which
is also in£uenced by the variable genetic background
of the respective patients.
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